专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2006124961A3 METHOD OF TREATING LYMPHANGIOLEIOMYOMATOSIS (LAM) 审中-公开
标题翻译：治疗淋巴细胞白血病的方法（LAM）
公开(公告)号：WO2006124961A3
公开(公告)日：2009-04-16
申请号：PCT/US2006019020
申请日：2006-05-16
申请人： CHILDRENS MEDICAL CENTER , FOLKMAN JUDAH , MOSES MARSHA A
发明人： FOLKMAN JUDAH , MOSES MARSHA A
IPC分类号： A01N37/18 , A61K31/65
CPC分类号： A61K31/65
摘要： The invention provides a method for the treatment of Lymphangioleiomyomatosis (LAM) in the human subject in need thereof. The method comprises administering to the subject an effective amount of doxycycline or a salt thereof. The invention further provides a method for monitoring the efficacy of treatment. Treatment efficacy is monitored by measuring MMP levels. Reduction in MMP levels indicates that the treatment is effective.
摘要翻译：本发明提供了在有需要的人类受试者中治疗淋巴管平滑肌瘤病（LAM）的方法。该方法包括向受试者施用有效量的多西环素或其盐。本发明还提供了用于监测治疗功效的方法。通过测量MMP水平监测治疗效果。 MMP水平的降低表明治疗有效。

2. 发明申请

WO2007016390A1 MATRIX METALLOPROTEINASE INHIBITORS FOR TREATING FATTY LIVER DISEASE 审中-公开
标题翻译：用于治疗脂肪肝疾病的基质金属蛋白酶抑制剂
公开(公告)号：WO2007016390A1
公开(公告)日：2007-02-08
申请号：PCT/US2006/029517
申请日：2006-07-28
申请人： CHILDREN'S MEDICAL CENTER CORPORATION , PUDER, Mark , MOSES, Marsha, A.
发明人： PUDER, Mark , MOSES, Marsha, A.
IPC分类号： A61K31/16 , A61P1/16
CPC分类号： A61K31/00 , A61K31/16
摘要： The present invention relates to a method for treating a fatty liver disease or disorder in a patient in need thereof. The method comprises administering at least one matrix metalloproteinase ("MMP") inhibitor to the patient. Fatty liver disease or disorders include, for example, NAFLD, NASH, ALD, fatty liver associated with chronic hepatitis infection, TPN, steroid treatment, tamoxifen treatment, gastrointestional operations, diabetes and Reye's Syndrome. The method is particularly useful when the fatty liver disease is associated with TPN and the patient is an infant or when the patient is obese. MMP inhibitors useful in the present invention include, for example, Marimastat, tetracyclines, Prinomastat, Batimastat, BAY 12-9566, AG3340 , BMS-275291, Neovastat , BB-3644, KB-R7785, TIMPl, TIMP2, doxycycline, minocycline, RS-130,830; CGS 27023A, Solimastat, Ro 32-3555, BMS-272591, and D2163. Marimastat is a preferred MMP inhibitor.
摘要翻译：本发明涉及在有需要的患者中治疗脂肪肝疾病或病症的方法。该方法包括向患者施用至少一种基质金属蛋白酶（“MMP”）抑制剂。脂肪肝疾病或病症包括例如NAFLD，NASH，ALD，与慢性肝炎感染相关的脂肪肝，TPN，类固醇治疗，他莫昔芬治疗，胃肠道手术，糖尿病和Reye综合征。当脂肪肝疾病与TPN相关并且患者是婴儿或当患者是肥胖时，该方法特别有用。可用于本发明的MMP抑制剂包括例如Marimastat，四环素，Prinomastat，Batimastat，BAY 12-9566，AG3340，BMS-275291，Neovastat，BB-3644，KB-R7785，TIMP1，TIMP2，多西环素，米诺环素，RS -130,830; CGS 27023A，Solimastat，Ro 32-3555，BMS-272591和D2163。马立马司他胺是一种优选的MMP抑制剂。

3. 发明申请

WO2006091412A2 ADAMTS-7 AS A BIOMARKER FOR CANCERS OF EPITHELIAL ORIGIN 审中-公开
标题翻译： ADAMTS-7作为上皮原始癌症的生物标志物
公开(公告)号：WO2006091412A2
公开(公告)日：2006-08-31
申请号：PCT/US2006/004985
申请日：2006-02-13
申请人： CHILDREN'S MEDICAL CENTER CORPORATION , MOSES, Marsha, A. , ROY, Roopali
发明人： MOSES, Marsha, A. , ROY, Roopali
IPC分类号： G01N33/574
CPC分类号： G01N33/57407 , G01N33/57496 , G01N2333/96486
摘要： ADAMTS-7 expression and activity are up regulated in patients that have cancers of epithelial origin. Accordingly, the present invention is directed to methods diagnosis of cancers of epithelial origin (e.g. breast cancer, prostate cancer, bladder cancer, brain cancer and hepatic cancer). In particular, the presence of ADAMTS-7 in a biological sample is indicative of cancer of epithelial origin. Thus, measuring the level of ADAMTS-7 in biological samples (e.g. urine or blood) provides a quick, easy, and safe screen that can be used to diagnose cancer in a patient.
摘要翻译： ADAMTS-7表达和活性在具有上皮性癌症的患者中上调。因此，本发明涉及上皮来源的癌症（例如乳腺癌，前列腺癌，膀胱癌，脑癌和肝癌）的方法诊断。特别地，生物样品中ADAMTS-7的存在表明上皮起源的癌症。因此，测量生物样品（例如尿液或血液）中ADAMTS-7的水平提供了可用于诊断患者癌症的快速，容易和安全的屏幕。

4. 发明申请

WO0231507A3 NON-INVASIVE ENZYME SCREEN FOR TISSUE REMODELLING-ASSOCIATED CONDITIONS 审中-公开
标题翻译：用于组织重组相关条件的非入侵性酶屏
公开(公告)号：WO0231507A3
公开(公告)日：2003-06-05
申请号：PCT/US0131980
申请日：2001-10-15
申请人： CHILDRENS MEDICAL CENTER , MOSES MARSHA A , YAN LI
发明人： MOSES MARSHA A , YAN LI
IPC分类号： G01N33/493 , C12Q1/00 , C12Q1/37 , G01N27/447 , G01N33/573 , G01N33/574
CPC分类号： G01N33/573 , C12Q1/37 , G01N33/574 , G01N33/57434 , G01N33/57488 , G01N2333/96486 , G01N2333/96494 , G01N2333/99 , G01N2550/00
摘要： methods and kits for diagnosing the presence of and prognosing the appearance of tissue remodelling-associated conditions, involving the presence of enzyme complexes in a biological sample, are disclosed. In particular, the method pertains to diagnosing the presence of or prognosing appearance of metastatic cancer by the identification of high molecular weight enzyme complexes comprising MMPs.
摘要翻译：公开了用于诊断存在并预测组织重塑相关病症的外观的方法和试剂盒，其涉及生物样品中酶复合物的存在。特别地，该方法涉及通过鉴定包含MMP的高分子量酶复合物来诊断转移性癌症的存在或预后。

5. 发明申请

WO2007098102A3 FREE NGAL AS A BIOMARKER FOR CANCER 审中-公开
公开(公告)号：WO2007098102A3
公开(公告)日：2007-08-30
申请号：PCT/US2007/004265
申请日：2007-02-16
申请人： CHILDRENS MEDICAL CENTER CORPORATION , MOSES, Marsha, A. , JANG, Jiang
发明人： MOSES, Marsha, A. , JANG, Jiang
IPC分类号： G01N33/574
摘要： Uncomplexed neutrophil gelatinase associated lipocalin (NGAL) is present at increased levels in individuals with atypical ductal hyperplasia (ADH)3 a major risk factor for future breast cancer development; in individuals that have ovarian cancer; and in individuals that have breast cancer, both invasive and noninvasive. Accordingly, the present invention is directed to measuring uncomplexed NGAL levels in urine as a primary screen to determine if an individual is either at risk of developing, or has developed cancer, e.g., cancer of epithelial origin including breast and ovarian cancer.

6. 发明申请

WO2006128179A2 METHOD FOR THE INHIBITION OF ANGIOGENESIS 审中-公开
标题翻译：抑制血管生成的方法
公开(公告)号：WO2006128179A2
公开(公告)日：2006-11-30
申请号：PCT/US2006020932
申请日：2006-05-30
申请人： CHILDRENS MEDICAL CENTER , MOSES MARSHA A , FORADORI MATTHEW J , LANGER ROBERT S
发明人： MOSES MARSHA A , FORADORI MATTHEW J , LANGER ROBERT S
CPC分类号： A61K31/00
摘要： The present invention is based on the discovery that Matrilin-1 has antiangiogenic and anticancer properties. The invention is directed to a method of treating a disease that responds to an inhibition of angiogenesis. Additionally, the invention can be applied to those at risk for developing a disease that responds to an inhibition of angiogenesis. The methods comprise administering to a mammal an effective angiogenesis-inhibiting amount of an Matrilin-1 consisting of Matrilin-1, Matrilin-1 fragment, analog, or derivative that is administered in a composition substantially free of other cartilage proteins.
摘要翻译：本发明是基于Matrilin-1具有抗血管生成和抗癌特性的发现。本发明涉及一种治疗对血管生成抑制作出反应的疾病的方法。此外，本发明可以应用于那些处于风险中的那些发展对血管生成的抑制作用的疾病。所述方法包括向哺乳动物施用有效的血管生成抑制量的由在基本上不含其它软骨蛋白的组合物中施用的Matrilin-1，Matrilin-1片段，类似物或衍生物组成的Matrilin-1。

7. 发明申请

WO2006124961A2 METHOD OF TREATING LYMPHANGIOLEIOMYOMATOSIS (LAM) 审中-公开
标题翻译：治疗淋巴细胞白血病的方法（LAM）
公开(公告)号：WO2006124961A2
公开(公告)日：2006-11-23
申请号：PCT/US2006/019020
申请日：2006-05-16
申请人： CHILDREN'S MEDICAL CENTER CORPORATION , FOLKMAN, Judah , MOSES, Marsha, A.
发明人： FOLKMAN, Judah , MOSES, Marsha, A.
IPC分类号： A61K31/65
CPC分类号： A61K31/65
摘要： The invention provides a method for the treatment of Lymphangioleiomyomatosis (LAM) in the human subject in need thereof. The method comprises administering to the subject an effective amount of doxycycline or a salt thereof. The invention further provides a method for monitoring the efficacy of treatment. Treatment efficacy is monitored by measuring MMP levels. Reduction in MMP levels indicates that the treatment is effective.
摘要翻译：本发明提供了在有需要的人类受试者中治疗淋巴管平滑肌瘤病（LAM）的方法。该方法包括向受试者施用有效量的多西环素或其盐。本发明还提供了用于监测治疗功效的方法。通过测量MMP水平监测治疗效果。 MMP水平的降低表明治疗有效。

8. 发明申请

WO2008067019A3 PHOSPHOLIPASE C AND METHOD OF USE 审中-公开
标题翻译：磷脂酶C及其使用方法
公开(公告)号：WO2008067019A3
公开(公告)日：2008-10-23
申请号：PCT/US2007080044
申请日：2007-10-01
申请人： UNIV COLORADO , VASIL MICHAEL L , VASIL ADRIANA , FERNANDEZ CECILIA A , STONEHOUSE MARTIN , MOSES MARSHA A
发明人： VASIL MICHAEL L , VASIL ADRIANA , FERNANDEZ CECILIA A , STONEHOUSE MARTIN , MOSES MARSHA A
IPC分类号： C12N15/55
CPC分类号： A61K38/465 , C12Y301/04003
摘要： The present invention provides a method for reducing angiogenesis using a phospholipase C.
摘要翻译：本发明提供了使用磷脂酶C来减少血管生成的方法。

9. 发明申请

WO2008067019A2 PHOSPHOLIPASE C AND METHOD OF USE 审中-公开
标题翻译：磷脂酶C及其使用方法
公开(公告)号：WO2008067019A2
公开(公告)日：2008-06-05
申请号：PCT/US2007/080044
申请日：2007-10-01
申请人： REGENTS OF UNIVERSITY OF COLORADO , VASIL, Michael, L. , VASIL, Adriana , FERNANDEZ, Cecilia, A. , STONEHOUSE, Martin , MOSES, Marsha, A.
发明人： VASIL, Michael, L. , VASIL, Adriana , FERNANDEZ, Cecilia, A. , STONEHOUSE, Martin , MOSES, Marsha, A.
IPC分类号： A61K38/46
CPC分类号： A61K38/465 , C12Y301/04003
摘要： The present invention provides a method for reducing angiogenesis using a phospholipase C.
摘要翻译：本发明提供了使用磷脂酶C来减少血管发生的方法。

10. 发明申请

WO2007098102A2 FREE NGAL AS A BIOMARKER FOR CANCER 审中-公开
标题翻译：免费NGAL作为癌症生物标志物
公开(公告)号：WO2007098102A2
公开(公告)日：2007-08-30
申请号：PCT/US2007004265
申请日：2007-02-16
申请人： CHILDRENS MEDICAL CT CORP , MOSES MARSHA A , JANG JIANG
发明人： MOSES MARSHA A , JANG JIANG
IPC分类号： G01N33/574
CPC分类号： G01N33/57496 , G01N33/57415 , G01N33/57449 , G01N33/57488 , G01N2333/47
摘要： Uncomplexed neutrophil gelatinase associated lipocalin (NGAL) is present at increased levels in individuals with atypical ductal hyperplasia (ADH)3 a major risk factor for future breast cancer development; in individuals that have ovarian cancer; and in individuals that have breast cancer, both invasive and noninvasive. Accordingly, the present invention is directed to measuring uncomplexed NGAL levels in urine as a primary screen to determine if an individual is either at risk of developing, or has developed cancer, e.g., cancer of epithelial origin including breast and ovarian cancer.
摘要翻译：未复合的中性粒细胞明胶酶相关脂质运载蛋白（NGAL）在非典型性导管增生（ADH）3患者中呈现增加的水平，这是未来乳腺癌发展的主要危险因素; 在患有卵巢癌的个体中; 以及患有乳腺癌的个体，无论是侵入性还是非侵入性。因此，本发明涉及测量尿中未复合的NGAL水平作为主要筛选，以确定个体是否处于发展癌症的风险中，或已经发展成癌症，例如上皮来源的癌症，包括乳腺癌和卵巢癌。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式